Sunovion Pharmaceuticals Tech Stack

Sunovion Pharmaceuticals uses 8 technology products and services including Linkedin Insight Tag, jsDelivr, Hyperion, and more. Explore Sunovion Pharmaceuticals's tech stack below.

  • Linkedin Insight Tag
    Analytics
  • jsDelivr
    Content Delivery Network
  • Hyperion
    Corporate Performance Management
  • Font Awesome
    Font Scripts
  • jQuery
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • Planisware
    Project Management
  • HSTS
    Security

Media & News

Sunovion Pharmaceuticals's Email Address Formats

Sunovion Pharmaceuticals uses at least 4 format(s):
Sunovion Pharmaceuticals Email FormatsExamplePercentage
first.middle@sunovion.comJohn.Michael@sunovion.com
38%
first.l@sunovion.comJohn.D@sunovion.com
25%
first.middlelast@sunovion.comJohn.MichaelDoe@sunovion.com
20%
firstlast@sunovion.comJohnDoe@sunovion.com
17%

Frequently Asked Questions

Where is Sunovion Pharmaceuticals's headquarters located?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals's main headquarters is located at 84 Waterford Dr Marlborough, MA 01752 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Sunovion Pharmaceuticals's phone number?

Minus sign iconPlus sign icon
You can contact Sunovion Pharmaceuticals's main corporate office by phone at +1-201-592-5044. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Sunovion Pharmaceuticals's stock symbol?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals is a publicly traded company; the company's stock symbol is SEPR.

What is Sunovion Pharmaceuticals's official website and social media links?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals's official website is sunovion.com and has social profiles on LinkedIn.

How much revenue does Sunovion Pharmaceuticals generate?

Minus sign iconPlus sign icon
As of February 2024, Sunovion Pharmaceuticals's annual revenue reached $750M.

What is Sunovion Pharmaceuticals's NAICS code?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals's NAICS code is 325412 - Pharmaceutical Preparation Manufacturing.

How many employees does Sunovion Pharmaceuticals have currently?

Minus sign iconPlus sign icon
As of February 2024, Sunovion Pharmaceuticals has approximately 1.2K employees across 6 continents, including North AmericaEuropeAsia. Key team members include Chief Medical Officer: A. L.Chief Scientific Officer: J. M.Chief Power Engineer: R. K.. Explore Sunovion Pharmaceuticals's employee directory with LeadIQ.

What industry does Sunovion Pharmaceuticals belong to?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Sunovion Pharmaceuticals use?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals's tech stack includes Linkedin Insight TagjsDelivrHyperionFont AwesomejQueryModernizrPlaniswareHSTS.

What is Sunovion Pharmaceuticals's email format?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals's email format typically follows the pattern of first.middle@sunovion.com. Find more Sunovion Pharmaceuticals email formats with LeadIQ.

When was Sunovion Pharmaceuticals founded?

Minus sign iconPlus sign icon
Sunovion Pharmaceuticals was founded in 2010.
Sunovion Pharmaceuticals

Sunovion Pharmaceuticals

Pharmaceutical ManufacturingMassachusetts, United States501-1000 Employees

We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us!⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀
====

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with serious neurological and psychiatric  conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Latuda® (lurasidone HCI), Aptiom® (eslicarbazepine acetate) Lonhala®  Magnair® (glycopyrrolate), and, most recently, KYNMOBI® (apomorphine HCI) sublingual film. 

Headquartered in Marlborough, MA Sunovion is an indirect, wholly owned subsidiary of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc. Find more information at www.sunovion.com and  connect on Twitter and Facebook @Sunovion.

LATUDA is a registered trademark of Sumitomo Pharma Co., Ltd.
APTIOM is used under license from BIAL.
KYNMOBI is a registered trademark of Sunovion Pharmaceuticals Inc.
LONHALA MAGNAIR is a registered trademarks of Sunovion Pharmaceuticals Inc.

© 2023 Sunovion Pharmaceuticals Inc.

To view our community guidelines, see here: bit.ly/3CozDLX

Section iconCompany Overview

Headquarters
84 Waterford Dr Marlborough, MA 01752 US
Phone number
+1-201-592-5044
Stock Symbol
SEPR
NAICS Code
325412 - Pharmaceutical Preparation Manufacturing
Founded
2010
Employees
501-1000

Section iconFunding & Financials

  • $100M$1B

    Sunovion Pharmaceuticals's revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $100M$1B

    Sunovion Pharmaceuticals's revenue is in the range of $100M$1B

© LeadIQ, Inc. All rights reserved.